Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 9/20 | 0.35 |
| ▸ | JAK2 | O60674 | 8/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113460 | 1.00 | PDE4B (0.48) | PDE4BNTRK1JAK2CNR1GPR55 | |
| SCHEMBL4113995 | 0.88 | PDE4B (0.53) | PDE4BCNR1GPR55TNKSHPGDS | |
| SCHEMBL4104197 | 0.88 | PDE4B (0.60) | PDE4BCNR1GPR55TNKSHPGDS | |
| SCHEMBL4104192 | 0.88 | PDE4B (0.60) | PDE4BCNR1GPR55TNKSHPGDS | |
| SCHEMBL4098136 | 0.86 | PDE4B (0.52) | PDE4BCNR1GPR55TNKSUSP30 | |
| SCHEMBL4106366 | 0.86 | PDE4B (0.52) | PDE4BCNR1GPR55TNKSUSP30 | |
| SCHEMBL871139 | 0.85 | PDE4B (0.40) | PDE4BNTRK1JAK2CNR1GPR55 | |
| SCHEMBL871140 | 0.85 | PDE4B (0.40) | PDE4BNTRK1JAK2CNR1GPR55 | |
| SCHEMBL5107421 | 0.84 | PDE4B (0.51) | PDE4BCNR1GPR55TNKSHPGDS | |
| SCHEMBL5107412 | 0.84 | PDE4B (0.51) | PDE4BCNR1GPR55TNKSHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233907-A1 | Pyridopyrimidine Derivatives and Their Use as PDE4 Inhibitors | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233907-A1 | Pyridopyrimidine Derivatives and Their Use as PDE4 Inhibitors | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233907-A1 | Pyridopyrimidine Derivatives and Their Use as PDE4 Inhibitors | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-1999130-A1 | PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | AstraZeneca AB (SE) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007108750-A1 | PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233907-A1 | Pyridopyrimidine Derivatives and Their Use as PDE4 Inhibitors | PDE4A, PDE4B, PDE12 | PDE4B 2/4885NTRK1 4199/4885JAK2 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.